Download or read book Model Assisted Bayesian Designs for Dose Finding and Optimization written by Ying Yuan and published by CRC Press. This book was released on 2022-11-11 with total page 239 pages. Available in PDF, EPUB and Kindle. Book excerpt: Bayesian adaptive designs provide a critical approach to improve the efficiency and success of drug development that has been embraced by the US Food and Drug Administration (FDA). This is particularly important for early phase trials as they form the basis for the development and success of subsequent phase II and III trials. The objective of this book is to describe the state-of-the-art model-assisted designs to facilitate and accelerate the use of novel adaptive designs for early phase clinical trials. Model-assisted designs possess avant-garde features where superiority meets simplicity. Model-assisted designs enjoy exceptional performance comparable to more complicated model-based adaptive designs, yet their decision rules often can be pre-tabulated and included in the protocol—making implementation as simple as conventional algorithm-based designs. An example is the Bayesian optimal interval (BOIN) design, the first dose-finding design to receive the fit-for-purpose designation from the FDA. This designation underscores the regulatory agency's support of the use of the novel adaptive design to improve drug development. Features Represents the first book to provide comprehensive coverage of model-assisted designs for various types of dose-finding and optimization clinical trials Describes the up-to-date theory and practice for model-assisted designs Presents many practical challenges, issues, and solutions arising from early-phase clinical trials Illustrates with many real trial applications Offers numerous tips and guidance on designing dose finding and optimization trials Provides step-by-step illustrations of using software to design trials Develops a companion website (www.trialdesign.org) to provide freely available, easy-to-use software to assist learning and implementing model-assisted designs Written by internationally recognized research leaders who pioneered model-assisted designs from the University of Texas MD Anderson Cancer Center, this book shows how model-assisted designs can greatly improve the efficiency and simplify the design, conduct, and optimization of early-phase dose-finding trials. It should therefore be a very useful practical reference for biostatisticians, clinicians working in clinical trials, and drug regulatory professionals, as well as graduate students of biostatistics. Novel model-assisted designs showcase the new KISS principle: Keep it simple and smart!

Download or read book Bayesian Designs for Phase I II Clinical Trials written by Ying Yuan and published by CRC Press. This book was released on 2017-12-19 with total page 310 pages. Available in PDF, EPUB and Kindle. Book excerpt: Reliably optimizing a new treatment in humans is a critical first step in clinical evaluation since choosing a suboptimal dose or schedule may lead to failure in later trials. At the same time, if promising preclinical results do not translate into a real treatment advance, it is important to determine this quickly and terminate the clinical evaluation process to avoid wasting resources. Bayesian Designs for Phase I–II Clinical Trials describes how phase I–II designs can serve as a bridge or protective barrier between preclinical studies and large confirmatory clinical trials. It illustrates many of the severe drawbacks with conventional methods used for early-phase clinical trials and presents numerous Bayesian designs for human clinical trials of new experimental treatment regimes. Written by research leaders from the University of Texas MD Anderson Cancer Center, this book shows how Bayesian designs for early-phase clinical trials can explore, refine, and optimize new experimental treatments. It emphasizes the importance of basing decisions on both efficacy and toxicity.

Download or read book Dose Finding Designs for Early Phase Cancer Clinical Trials written by Takashi Daimon and published by Springer. This book was released on 2019-05-21 with total page 133 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides a comprehensive introduction to statistical methods for designing early phase dose-finding clinical trials. It will serve as a textbook or handbook for graduate students and practitioners in biostatistics and clinical investigators who are involved in designing, conducting, monitoring, and analyzing dose-finding trials. The book will also provide an overview of advanced topics and discussions in this field for the benefit of researchers in biostatistics and statistical science. Beginning with backgrounds and fundamental notions on dose finding in early phase clinical trials, the book then provides traditional and recent dose-finding designs of phase I trials for, e.g., cytotoxic agents in oncology, to evaluate toxicity outcome. Included are rule-based and model-based designs, such as 3 + 3 designs, accelerated titration designs, toxicity probability interval designs, continual reassessment method and related designs, and escalation overdose control designs. This book also covers more complex and updated dose-finding designs of phase I-II and I/II trials for cytotoxic agents, and cytostatic agents, focusing on both toxicity and efficacy outcomes, such as designs with covariates and drug combinations, maximum tolerated dose-schedule finding designs, and so on.

Download or read book Bayesian Adaptive Dose finding Clinical Trial Designs with Late onset Outcomes written by Yifei Zhang and published by . This book was released on 2021 with total page 212 pages. Available in PDF, EPUB and Kindle. Book excerpt: The late-onset outcome issue is common in early phase dose- nding clinical trials. This problem becomes more intractable in phase I/II clinical trials because both toxicity and e cacy responses are subject to the late-onset outcome issue. The existing methods applying for the phase I trials cannot be used directly for the phase I/II trial due to a lack of capability to model the joint toxicity{e cacy distribution. We propose a conditional weighted likelihood (CWL) method to circumvent this issue. The key idea of the CWL method is to decompose the joint probability into the product of marginal and conditional probabilities and then weight each probability based on each patient's actual follow-up time. We further extend the proposed method to handle more complex situations where the late-onset outcomes are competing risks or semicompeting risks outcomes. We treat the late-onset competing risks/semi-competing risks outcomes as missing data and develop a series of Bayesian data-augmentation methods to e ciently impute the missing data and draw the posterior samples of the parameters of interest. We also propose adaptive dose- nding algorithms to allocate patients and identify the optimal biological dose during the trial. Simulation studies show that the proposed methods yield desirable operating characteristics and outperform the existing methods.

Download or read book The Application of Bayesian Adaptive Design and Markov Model in Clinical Trials written by Xiaoyu Lu and published by . This book was released on 2013 with total page 1110 pages. Available in PDF, EPUB and Kindle. Book excerpt: In this research, two new designs in clinical trials are proposed. The first problem is a new Bayesian adaptive dose-finding design and its application in an oncology clinical trial. This design is used for phase IB studies with the biomarker as the endpoint and with the fewer patients. The second problem is another new Bayesian adaptive dose-finding design with longitudinal analysis and its application in phase II depression clinical trial. This design is best fit for phase II dosing-finding clinical trials with clinical endpoints. MTD information has been obtained before the trials. In adaptive dose-finding clinical trials, the strategy is to reduce the allocation of patients to non-informative doses and also save the trial cost. Bayesian adaptive dose finding design has the ability to utilize accumulating data obtained in real time to alter the course of the trial, thereby enabling dynamic allocation to different dosing groups and dropping of ineffective dosing group earlier. In this research, Bayesian adaptive method is used as a new and useful approach that applies to phase IB and phase II dose-finding clinical trials to evaluate safety and efficacy of the study treatment. Response model and Normal Dynamic Linear Models (NDLMs) are applied in stages 1-4. Conditional probability for each parameter in the model is derived using appropriate prior distributions. Markov Chain Monte Carlo (MCMC) method is used to do the simulation. Model parameters with meaningful prior distributions and the posterior quantities are obtained to evaluate the trial results and they help to determine the optimal dose level which can be used in later studies. Simulations are done for different scenarios in the two designs and used to validate the model. Five-thousand simulation trials are conducted to verify the repeatability of the results. The posterior probability of success for the trial is greater than 90% based on the simulation results. The results give clearer idea if one needs to go further to test new dose levels based on the thorough evaluation of the existing partial data. Compared with the other adaptive dose finding strategy, the proposed Bayesian adaptive designs are sensitive and robust to help the investigators draw conclusion as early as possible. The designs can also reduce sample size substantially which in turn leads to savings in cost and time. Continuous-time Markov model has the advantage over the traditional survival model and can be used to describe disease as a series of probable transitions between health states. This is an attractive feature since it provides the ability to describe the course of disease over time. It can also describe and estimate expected survival in clinical cohort. In this research, continuous-time Markov model is used in the time-to-event analysis in a phase II oncology trial. Six states are defined in the Markov chain which is used in time to progression analysis for 36 patients with neuroendocrine carcinoma. The transition probability matrix P is defined and used to iterate future transition and survival probabilities. The estimate from matrix analysis shows that the results are reliable and comparable with the Kaplan-Meier results.

Download or read book Bayesian Adaptive Methods for Phase I Clinical Trials written by Ruitao Lin and published by . This book was released on 2017-01-26 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: This dissertation, "Bayesian Adaptive Methods for Phase I Clinical Trials" by Ruitao, Lin, 林瑞涛, was obtained from The University of Hong Kong (Pokfulam, Hong Kong) and is being sold pursuant to Creative Commons: Attribution 3.0 Hong Kong License. The content of this dissertation has not been altered in any way. We have altered the formatting in order to facilitate the ease of printing and reading of the dissertation. All rights not granted by the above license are retained by the author. Abstract: The primary objective of phase I dose-finding trials is to determine the maximum tolerated dose (MTD), which is typically defined as the dose with the dose-limiting toxicity probability closest to the target toxicity probability. The American Society of Clinical Oncology (ASCO) recently published an update of the ASCO policy statement to call for new phase I trial designs to allow for more efficient escalation to the therapeutic dose levels in order to cope with the changing landscape in cancer research. In this thesis, innovative and robust designs for single- or multiple-agent phase I dose-finding trials are studied. To enhance robustness and efficiency, two nonparametric methods are proposed to locate the MTD in single-agent phase I clinical trials without imposing any parametric assumption on the underlying distribution of the toxicity curve. First, a uniformly most powerful Bayesian interval (UMPBI) design is developed for dose finding, where the optimal interval is determined by the rejection region of the uniformly most powerful Bayesian test. UMPBI is easy to implement and can be nicely interpreted. Compared with existing interval designs, the proposed UMPBI design exhibits a unique feature of convergence to the MTD. Next, a nonparametric overdose control (NOC) method is proposed by casting dose finding in a Bayesian model selection framework. Each dose assignment under NOC is determined such that the posterior probability of overdosing is controlled. In addition, NOC is incorporated with a fractional imputation method to deal with late-onset toxicity outcomes. Both of the UMPBI and NOC designs are flexible, as well as possessing sound theoretical support and desirable numerical performance. In the era of precision medicine, combination therapy is playing an increasingly important role in drug development. However, drug combinations often lead to a high-dimensional dose searching space compared to conventional single-agent dose finding, especially when three or more drugs are combined for treatment. Most of the current dose-finding designs aim to quantify the toxicity probability space using certain prespecified yet complicated models. Not only do these models characterize each individual drug's toxicity profile, but they also need to quantify their interaction effects, which often leads to multi-parameter models. In order to stabilize the current practice of dose finding in drug-combination trials with limited sample sizes, a random walk Bayesian optimal interval (RW-BOIN) design and a Bootstrap aggregating continual reassessment method (Bagging CRM) are proposed. RW-BOIN is built on the basis of the single-agent BOIN design, and it can be utilized to tackle high-dimensional dose-finding problems. A convergence theorem is established to ensure the validity of RW-BOIN. On the other hand, Bagging CRM implements a dimension reduction technique and some ensemble methods in machine learning, so that the toxicity probability space can be stably reduced to a one-dimensional searching line. Simulation studies show that both RW-BOIN and Bagging CRM have comparative and robust operating characteristics compared with existing approaches under various dose-toxicity scenarios. All of the proposed methods are exemplified with real phase I dose-finding trials. Subjects: Bayesian statistical decision theory Clinical trials - Statistical methods

Download or read book Design and Analysis of Pragmatic Trials written by Song Zhang and published by CRC Press. This book was released on 2023-05-16 with total page 215 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book begins with an introduction of pragmatic cluster randomized trials (PCTs) and reviews various pragmatic issues that need to be addressed by statisticians at the design stage. It discusses the advantages and disadvantages of each type of PCT, and provides sample size formulas, sensitivity analyses, and examples for sample size calculation. The generalized estimating equation (GEE) method will be employed to derive sample size formulas for various types of outcomes from the exponential family, including continuous, binary, and count variables. Experimental designs that have been frequently employed in PCTs will be discussed, including cluster randomized designs, matched-pair cluster randomized design, stratified cluster randomized design, stepped-wedge cluster randomized design, longitudinal cluster randomized design, and crossover cluster randomized design. It demonstrates that the GEE approach is flexible to accommodate pragmatic issues such as hierarchical correlation structures, different missing data patterns, randomly varying cluster sizes, etc. It has been reported that the GEE approach leads to under-estimated variance with limited numbers of clusters. The remedy for this limitation is investigated for the design of PCTs. This book can assist practitioners in the design of PCTs by providing a description of the advantages and disadvantages of various PCTs and sample size formulas that address various pragmatic issues, facilitating the proper implementation of PCTs to improve health care. It can also serve as a textbook for biostatistics students at the graduate level to enhance their knowledge or skill in clinical trial design. Key Features: Discuss the advantages and disadvantages of each type of PCTs, and provide sample size formulas, sensitivity analyses, and examples. Address an unmet need for guidance books on sample size calculations for PCTs; A wide variety of experimental designs adopted by PCTs are covered; The sample size solutions can be readily implemented due to the accommodation of common pragmatic issues encountered in real-world practice; Useful to both academic and industrial biostatisticians involved in clinical trial design; Can be used as a textbook for graduate students majoring in statistics and biostatistics.

Download or read book Case Studies in Bayesian Methods for Biopharmaceutical CMC written by Paul Faya and published by CRC Press. This book was released on 2022-12-15 with total page 354 pages. Available in PDF, EPUB and Kindle. Book excerpt: The subject of this book is applied Bayesian methods for chemistry, manufacturing, and control (CMC) studies in the biopharmaceutical industry. The book has multiple authors from industry and academia, each contributing a case study (chapter). The collection of case studies covers a broad array of CMC topics, including stability analysis, analytical method development, specification setting, process development and optimization, process control, experimental design, dissolution testing, and comparability studies. The analysis of each case study includes a presentation of code and reproducible output. This book is written with an academic level aimed at practicing nonclinical biostatisticians, most of whom have graduate degrees in statistics. • First book of its kind focusing strictly on CMC Bayesian case studies • Case studies with code and output • Representation from several companies across the industry as well as academia • Authors are leading and well-known Bayesian statisticians in the CMC field • Accompanying website with code for reproducibility • Reflective of real-life industry applications/problems

Download or read book Statistical Analytics for Health Data Science with SAS and R written by Jeffrey Wilson and published by CRC Press. This book was released on 2023-03-27 with total page 280 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book aims to compile typical fundamental-to-advanced statistical methods to be used for health data sciences. Although the book promotes applications to health and health-related data, the models in the book can be used to analyze any kind of data. The data are analyzed with the commonly used statistical software of R/SAS (with online supplementary on SPSS/Stata). The data and computing programs will be available to facilitate readers’ learning experience. There has been considerable attention to making statistical methods and analytics available to health data science researchers and students. This book brings it all together to provide a concise point-of-reference for the most commonly used statistical methods from the fundamental level to the advanced level. We envisage this book will contribute to the rapid development in health data science. We provide straightforward explanations of the collected statistical theory and models, compilations of a variety of publicly available data, and illustrations of data analytics using commonly used statistical software of SAS/R. We will have the data and computer programs available for readers to replicate and implement the new methods. The primary readers would be applied data scientists and practitioners in any field of data science, applied statistical analysts and scientists in public health, academic researchers, and graduate students in statistics and biostatistics. The secondary readers would be R&D professionals/practitioners in industry and governmental agencies. This book can be used for both teaching and applied research.

Download or read book Digital Therapeutics written by Oleksandr Sverdlov and published by CRC Press. This book was released on 2022-12-06 with total page 462 pages. Available in PDF, EPUB and Kindle. Book excerpt: One of the hallmarks of the 21st century medicine is the emergence of digital therapeutics (DTx)—evidence-based, clinically validated digital technologies to prevent, diagnose, treat, and manage various diseases and medical conditions. DTx solutions have been gaining interest from patients, investors, healthcare providers, health authorities, and other stakeholders because of the potential of DTx to deliver equitable, massively scalable, personalized and transformative treatments for different unmet medical needs. Digital Therapeutics: Scientific, Statistical, Clinical, and Regulatory Aspects is an unparalleled summary of the current scientific, statistical, developmental, and regulatory aspects of DTx which is poised to become the fastest growing area of the biopharmaceutical and digital medicine product development. This edited volume intends to provide a systematic exposition to digital therapeutics through 19 peer-reviewed chapters written by subject matter experts in this emerging field. This edited volume is an invaluable resource for business leaders and researchers working in public health, healthcare, digital health, information technology, and biopharmaceutical industries. It will be also useful for regulatory scientists involved in the review of DTx products, and for faculty and students involved in an interdisciplinary research on digital health and digital medicine. Key Features: Provides the taxonomy of the concepts and a navigation tool for the field of DTx. Covers important strategic aspects of the DTx industry, thereby helping investors, developers, and regulators gain a better appreciation of the potential value of DTx. Expounds on many existing and emerging state-of-the art scientific and technological tools, as well as data privacy, ethical and regulatory considerations for DTx product development. Presents several case studies of successful development of some of the most remarkable DTx products. Provides some perspectives and forward-looking statements on the future of digital medicine.

Download or read book Controlled Epidemiological Studies written by Marie Reilly and published by CRC Press. This book was released on 2023-05-26 with total page 436 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book covers classic epidemiological designs that use a reference/control group, including case-control, case-cohort, nested case-control and variations of these designs, such as stratified and two-stage designs. It presents a unified view of these sampling designs as representations of an underlying cohort or target population of interest. This enables various extended designs to be introduced and analysed with a similar approach: extreme sampling on the outcome (extreme case-control design) or on the exposure (exposure-enriched, exposure-density, countermatched), designs that re-use prior controls and augmentation sampling designs. Further extensions exploit aggregate data for efficient cluster sampling, accommodate time-varying exposures and combine matched and unmatched controls. Self-controlled designs, including case-crossover, self-controlled case series and exposure-crossover, are also presented. The test-negative design for vaccine studies and the use of negative controls for bias assessment are introduced and discussed. This book is intended for graduate students in biostatistics, epidemiology and related disciplines, or for health researchers and data analysts interested in extending their knowledge of study design and data analysis skills. This book Bridges the gap between epidemiology and the more mathematically oriented biostatistics books. Assembles the wealth of epidemiological knowledge about observational study designs that is scattered over several decades of scientific publications. Illustrates the performance of methods in real research applications. Provides guidelines for implementation in standard software packages (Stata, R). Includes numerous exercises, covering simple mathematical proofs, consideration of proposed or published designs, and practical data analysis.

Download or read book Value of Information for Healthcare Decision Making written by Anna Heath and published by CRC Press. This book was released on 2024-02-08 with total page 317 pages. Available in PDF, EPUB and Kindle. Book excerpt: Value of Information for Healthcare Decision-Making introduces the concept of Value of Information (VOI) use in health policy decision-making to determine the sensitivity of decisions to assumptions, and to prioritise and design future research. These methods, and their use in cost-effectiveness analysis, are increasingly acknowledged by health technology assessment authorities as vital. Key Features: Provides a comprehensive overview of VOI Simplifies VOI Showcases state-of-the-art techniques for computing VOI Includes R statistical software package Provides results when using VOI methods Uses realistic decision model to illustrate key concepts The primary audience for this book is health economic modellers and researchers, in industry, government, or academia, who wish to perform VOI analysis in health economic evaluations. It is relevant for postgraduate researchers and students in health economics or medical statistics who are required to learn the principles of VOI or undertake VOI analyses in their projects. The overall goal is to improve the understanding of these methods and make them easier to use.

Download or read book Statistical Methods in Health Disparity Research written by J. Sunil Rao and published by CRC Press. This book was released on 2023-07-11 with total page 341 pages. Available in PDF, EPUB and Kindle. Book excerpt: A health disparity refers to a higher burden of illness, injury, disability, or mortality experienced by one group relative to others attributable to multiple factors including socioeconomic status, environmental factors, insufficient access to health care, individual risk factors, and behaviors and inequalities in education. These disparities may be due to many factors including age, income, and race. Statistical Methods in Health Disparity Research will focus on their estimation, ranging from classical approaches including the quantification of a disparity, to more formal modeling, to modern approaches involving more flexible computational approaches. Features: Presents an overview of methods and applications of health disparity estimation First book to synthesize research in this field in a unified statistical framework Covers classical approaches, and builds to more modern computational techniques Includes many worked examples and case studies using real data Discusses available software for estimation The book is designed primarily for researchers and graduate students in biostatistics, data science, and computer science. It will also be useful to many quantitative modelers in genetics, biology, sociology, and epidemiology.

Download or read book Case Studies in Innovative Clinical Trials written by Kristine Broglio and published by CRC Press. This book was released on 2023-11-27 with total page 303 pages. Available in PDF, EPUB and Kindle. Book excerpt: Drug development is a strictly regulated area. As such, marketing approval of a new drug depends heavily, if not exclusively, on evidence generated from clinical trials. Drug development has seen tremendous innovation in science and technology that has revolutionized the treatment of some diseases. And yet, the statistical design and practical conduct of the clinical trials used to test new therapeutics for safety and efficacy have changed very little over the decades. Our approach to clinical trials is steeped in convention and tradition. The large, fixed, randomized controlled trial methods that have been the gold standard are well understood and expected by many trial stakeholders. However, this approach is not well suited to all aspects of modern drug development and the current competitive landscape. We now see new therapies that target a small fraction of the patient population, rare diseases with high unmet medical needs, and pediatric populations that must wait for years for new drug approvals from the time that therapies are approved in adults. Large randomized clinical trials are at best inefficient and at worst completely infeasible in many modern clinical settings. Advances in technology and data infrastructure call for innovations in clinical trial design. Despite advances in statistical methods, the availability of information, and computing power, the actual experience with innovative design in clinical trials across industry and academia is limited. This book will be an important showcase of the potential for these innovative designs in modern drug development and will be an important resource to guide those who wish to undertake them for themselves. This book is ideal for professionals in the pharmaceutical industry and regulatory agencies, but it will also be useful to academic researchers, faculty members, and graduate students in statistics, biostatistics, public health, and epidemiology due to its focus on innovation. Key Features: Is written by pharmaceutical industry experts, academic researchers, and regulatory reviewers; this is the first book providing a comprehensive set of case studies related to statistical methodology, implementation, regulatory considerations, and communication of complex innovative trial design Has a broad appeal to a multitude of readers across academia, industry, and regulatory agencies Each contribution is a practical case study that can speak to the benefits of an innovative approach but also balance that with the real-life challenges encountered A complete understanding of what is actually being done in modern clinical trials will broaden the reader’s capabilities and provide examples to first mimic and then customize and expand upon when exploring these ideas on their own

Download or read book ROC Analysis for Classification and Prediction in Practice written by Christos Nakas and published by CRC Press. This book was released on 2023-05-15 with total page 234 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book presents a unified and up-to-date introduction to ROC methodologies, covering both diagnosis (classification) and prediction. The emphasis is on the conceptual underpinning of ROC analysis and the practical implementation in diverse scientific fields. A plethora of examples accompany the methodologic discussion using standard statistical software such as R and STATA. The book arrives after two decades of intensive growth in both the methods and the applications of ROC analysis and presents a new synthesis. The authors provide a contemporary, integrated exposition of ROC methodology for both classification and prediction and include material on multiple-class ROC. This book avoids lengthy technical exposition and provides code and datasets in each chapter. Receiver Operating Characteristic Analysis for Classification and Prediction is intended for researchers and graduate students, but will also be useful for those that use ROC analysis in diverse disciplines such as diagnostic medicine, bioinformatics, medical physics, and perception psychology.

Download or read book Quantitative Methods for Precision Medicine written by Rongling Wu and published by CRC Press. This book was released on 2022-12-26 with total page 307 pages. Available in PDF, EPUB and Kindle. Book excerpt: Modern medicine is undergoing a paradigm shift from a "one-size-fits-all" strategy to a more precise patient-customized therapy and medication plan. While the success of precision medicine relies on the level of pharmacogenomic knowledge, dissecting the genetic mechanisms of drug response in a sufficient detail requires powerful computational tools. Quantitative Methods for Precision Medicine: Pharmacogenomics in Action presents the advanced statistical methods for mapping pharmacogenetic control by integrating pharmacokinetic and pharmacodynamic principles of drug-body interactions. Beyond traditional reductionist-based statistical genetic approaches, statistical formulization in this book synthesizes elements of multiple disciplines to infer, visualize, and track how pharmacogenes interact together as an intricate but well-coordinated system to mediate patient-specific drug response. Features: Functional and systems mapping models to characterize the genetic architecture of multiple medication processes Statistical methods for analyzing informative missing data in pharmacogenetic association studies Functional graph theory of inferring genetic interaction networks from association data Leveraging the concept of epistasis to capture its bidirectional, signed and weighted properties Modeling gene-induced cell-cell crosstalk and its impact on drug response A graph model of drug-drug interactions in combination therapies Critical methodological issues to improve pharmacogenomic research as the cornerstone of precision medicine This book is suitable for graduate students and researchers in the fields of biology, medicine, bioinformatics and drug design and delivery who are interested in statistical and computational modelling of biological processes and systems. It may also serve as a major reference for applied mathematicians, computer scientists, and statisticians who attempt to develop algorithmic tools for genetic mapping, systems pharmacogenomics and systems biology. It can be used as both a textbook and research reference. Professionals in pharmaceutical sectors who design drugs and clinical doctors who deliver drugs will also find it useful.

Download or read book Numerical Techniques for Direct and Large Eddy Simulations written by Xi Jiang and published by CRC Press. This book was released on 2016-04-19 with total page 284 pages. Available in PDF, EPUB and Kindle. Book excerpt: Compared to the traditional modeling of computational fluid dynamics, direct numerical simulation (DNS) and large-eddy simulation (LES) provide a very detailed solution of the flow field by offering enhanced capability in predicting the unsteady features of the flow field. In many cases, DNS can obtain results that are impossible using any other me